New data presented today at The International Liver Congress 2016 in Barcelona, Spain, demonstrates that the drug sitagliptin - more commonly used to treat diabetes - was no more effective than placebo for reducing non-alcoholic ...
Apr 16, 2016
0
4
Adding coffee to the diet of people with non-alcoholic fatty liver disease (NAFLD) could help reverse the condition, according to a new study conducted in mice presented at The International Liver Congress 2016 in Barcelona, ...
Apr 13, 2016
0
19
Liver damage caused by the typical "Western diet" - one high in fat, sugar and cholesterol that's common in developed countries such as the United States - may be difficult to reverse even if diet is generally improved, a ...
Jan 13, 2016
1
115
Scientists at the Gladstone Institutes have discovered an unusual regulator of body weight and the metabolic syndrome: a molecular mechanism more commonly associated with brain cells. Lowering levels of P75 neurotrophin receptor ...
Jan 12, 2016
0
190
Emerging evidence suggests that transgender women have a higher risk of developing cardiovascular disease and type 2 diabetes compared with men and women in the general population. A preliminary study to be presented at Cardiovascular, ...
Nov 19, 2015
0
14
Maple syrup, a concentrated sap from the maple tree Acer saccarum, is used as a sweet alternative to refined sugar across the world. Scientists are becoming interested in maple syrup as a source of beneficial compounds such ...
Oct 27, 2015
0
26
Researchers at Beth Israel Deaconess Medical Center (BIDMC) have identified a new vitamin B3 pathway that regulates liver metabolism. The discovery provides an opportunity to pursue the development of novel drug therapies ...
Aug 6, 2015
0
102
Around-the-clock rhythms guide nearly all physiological processes in animals and plants. Each cell in the body contains special proteins that act on one another in interlocking feedback loops to generate near-24 hour oscillations ...
Jun 4, 2015
0
80
Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic ...
Apr 23, 2015
0
5
(HealthDay)—Reductions in liver fat or visceral adipose tissue (VAT) do not differ significantly with the dose or intensity of aerobic exercise, according to a study published online April 8 in the Journal of Hepatology.
Apr 10, 2015
0
28
